46061E4B-5256-42AD-BA9A-FBCEBE92B09A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.763469119579501
- age_years
- 77
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.612
- MYC_TARGETS_V1+0.608
- G2M_CHECKPOINT+0.583
- DNA_REPAIR+0.541
- MTORC1_SIGNALING+0.528
- MYC_TARGETS_V2+0.513
- GLYCOLYSIS+0.505
- OXIDATIVE_PHOSPHORYLATION+0.484
- HYPOXIA+0.480
- UNFOLDED_PROTEIN_RESPONSE+0.460
Top 10 suppressed
- KRAS_SIGNALING_DN-0.375
- PANCREAS_BETA_CELLS-0.257
- MYOGENESIS-0.163
- SPERMATOGENESIS-0.136
- APICAL_SURFACE-0.057
- WNT_BETA_CATENIN_SIGNALING-0.005
- HEDGEHOG_SIGNALING+0.028
- KRAS_SIGNALING_UP+0.074
- ESTROGEN_RESPONSE_EARLY+0.091
- BILE_ACID_METABOLISM+0.094
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.976 |
| 2 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.972 |
| 3 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.971 |
| 4 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.970 |
| 5 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.969 |
| 6 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.965 |
| 7 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.964 |
| 8 | 61D1FD4D-F0FF-4D89-B26F-C1102685ED9D | — | — | 0.964 |
| 9 | EBE58DF8-7300-4D3E-9672-A4E7ADF46113 | — | — | 0.963 |
| 10 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.962 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.612 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.608 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.583 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.541 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.528 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.513 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.505 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.484 | Remibrutinib | — uncovered |
| HYPOXIA | 0.480 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.460 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.417 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.416 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.411 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.411 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.411 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.408 | Inavolisib | — uncovered |
| APOPTOSIS | 0.399 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.385 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.372 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.353 | Idelalisib | — uncovered |